Central Involvement of 5-HT in the Erectile Process
Serotonergic involvement in the brain and sexual behavior, both in humans and in animals, is established (Hull, Muschamp, & Sato, 2004) . The paraventricular nucleus may play a role in penile erection via the control of descending serotonergic raphe-spinal neurons (Bancila et al., 2002) . Central activation of 5-H(2A) and 5-HT(2C) receptors facilitates (Bancila et al., 1999; Brotto & Gorzalka, 2000; Steers, 1990) whereas central activation of the 5-HT(1A) receptor inhibits erection (Ahlenius, Larsson, & Arvidsson, 1989; Rehman et al., 1999) . Serotonergic drugs that act centrally can affect erectile function. Serotonin-specific reuptake inhibitors (SSRIs) such as paroxetine can cause ED (Ahn et al., 2005) . Paroxetine increases the incidence of ED via inhibition of nitric oxide synthase (NOS) activity (Angulo et al., 2001) . However, other SSRIs such as citalopram may affect sexual function to a lesser degree and it does not inhibit NOS activity (Angulo et al., 2001) . Furthermore, trazodone, an antidepressant, can cause priapism via its major metabolite, metachlorophenylpiperazine (m-cpp, a neuronal 5-HT releaser) (Myrick, Markowitz, & Henderson, 1998; Rothman & Baumann, 2002) . Overall, the pathophysiological mechanism underlying how some serotonergic drugs influence erectile function is still unclear.
Peripheral Involvement of 5-HT in the Erectile Process
There is evidence supporting a role for peripheral 5-HT involvement at the penile organ/vessel level. S erotonin (5-hydroxytryptamine, 5-HT) is a monoamine transmitter, which is stored in both peripheral endocrine and neuronal cells. It is one of the oldest neurotransmitters in evolution and is implicated in conditions such as hypertension, anxiety, irritable bowel syndrome, and depression. There are 7 distinct classes of serotonergic receptors (5-HT[1] to 5-HT[7]) based on their structural and functional characteristics. These receptors are sited both in the central and peripheral nervous system, as well as in a number of nonneuronal cells in the gut, cardiovascular system, and platelets. Serotonergic receptors are part of the G-protein-coupled receptor superfamily with the exception of the 5-HT(3) receptor, which is a ligand-gated ion channel (Martin & Humphrey, 1994) .
Erectile dysfunction (ED) is associated with dyslipidemia, diabetes, hypertension, and atherosclerosis (Vrentzos, Paraskevas, & Mikhailidis, 2007) . 5-HT might be implicated in the pathogenesis of ED in that there is a significant increase in plasma 5-HT levels (and a decrease in intraplatelet levels) in patients with diabetes and peripheral arterial disease compared with normal controls (Barradas, Gill, Fonseca, Mikhailidis, & Dandona, 1988) . These 5-HT changes are likely to be related to platelet hyperactivity.
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Using organ bath and electrical field stimulation studies, we demonstrated the presence of neuronally derived 5-HT in the human corpus cavernosum, which acts on 5-HT(2A) receptors (Lau et al., 2006) . In the same study, 5-HT caused human cavernosal contraction via the 5-HT(2A), 5-HT(1A), and 5-HT(4) receptor subtypes (in order of decreasing potency). In an another organ bath study, a biphasic serotonergic response was observed in the rabbit corpus cavernosum, a transient relaxation via 5-HT(3) receptor followed by sustained contraction via 5-HT(2A) receptors (Lau, Thompson, Mumtaz, Morgan, & Mikhailidis, in press) .
Other organ bath studies support a role for the peripheral serotonergic pathway in the erectile process. Esen, Gidener, Guler, Guven, and Kirkali (1997) reported that the 5-HT-mediated contractile response in human penile veins was augmented in patients with veno-occlusive disease. A rabbit study (Furukawa, Nagao, Ishii, & Uchiyama, 2003) indicated the involvement of 5-HT(1A) and 5-HT(2A) receptors in contracting cavernosal smooth muscle. A human study by Uckert et al. (2003) demonstrated a 5-HT(1A)mediated contractile response in corpus cavernosal strips. Furthermore, Uckert et al. (2003) identified a significant increase in 5-HT levels in cavernous serum from flaccidity to tumescence and rigidity and the detumescence phase in normal human individuals. This variation in local 5-HT levels at different stages of erection may have a role in ensuring detumescence.
An in vivo technique whereby animals are anesthetized and given chemicals via intravascular, intraperitoneal, or subcutaneous route followed by cavernosal nerve stimulation and/or measurement of intracavernosal pressure (ICP) has been used to study the effect of serotonergic agents on erection. Hayes and Adaikan (2002) reported the involvement of 5-HT(1A) and 5-HT(1B) receptors in erection in a rabbit study. Previous studies on penile vessels demonstrated a 5-HT-mediated inhibitory action on penile erection (decreased ICP) in rats due to vasoconstriction of the cavernosal arteries (Finberg & Vardi, 1990) . Recently, Kimura, Naitou, Wanibuchi, and Yamaguchi (2006) demonstrated in a rat study that the 5-HT(2C) receptor is also involved in tumescence (increased ICP).
5-HT may also play a role in the pathogenesis of premature ejaculation (PE). PE is a frequent male sexual complaint (Giuliano, 2007; Waldinger, 2007) . SSRIs may have a role in the treatment of PE (Giuliano, 2007; Waldinger, 2007) . However, it is believed that phosphodiesterase type 5 inhibitors should not be prescribed to men with PE with normal erectile function but may be used if PE is accompanied by ED (Giuliano, 2007; Waldinger, 2007) . The presence of PE may also represent a psychological contributor to ED.
Conclusions 5-HT may be involved in fine-tuning cavernosal responses and the success of the complex erectile process. The peripheral serotonergic pathway warrants more extensive investigation to establish whether targeting it is a viable and safe option in treating ED.
